INTRODUCTION: Elevated level of Plasminogen Activator Inhibitor-I (PAI-1) reduces the ef®ciency of the ®brinolytic system and has been linked to an increased risk of cardiovascular disease. PAI-1 is produced in several tissues including adipose tissue. Thus, PAI-1 may be a factor for the enhanced thrombogenesis seen in association with obesity. We studied the regulation of PAI-1 in human adipose tissue by different cytokinesahormones and PPARligands. METHODS: Human subcutaneous adipose tissue fragments were cultures in vitro and PAI-1 production into the medium was measured by ELISA. The PAI-1 gene-expression in the adipose tissue fragments was measured by real-time RT-PCR. The effects of cytokines, estrogen, dexamethasone(DEXA), PPAR-a agonist (ETYA) and PPAR-g agonists (Ciglitazone) were studied. In addition, the effects of the PPAR-agonists were studied using human pre-adipocytes in primary culture. RESULTS: The PAI-production and PAI-1 gene-expression was signi®cantly stimulated by incubation with TNF-a, TGF-b and IL-1b, whereas IL-6 did not in¯uence adipose tissue PAI-production. Estrogen signi®cantly attenuated the IL-1 induced increase in PAI-1 production by 17.8% (p`0.05) and estrogen also attenuated the IL-1 effect on PAI-1 gene-expression. Short-term incubation (up to 8 h) with DEXA stimulated PAI-1 production, whereas prolonged incubations (from 8 to 72 h) signi®cantly inhibited the IL-1 induced increase in PAI-1 production and gene-expression. Neither of the PPAR agonists had any effects on PAI-1 production in human adipose tissue fragments (neither basal nor IL-1 stimulated) for incubation up to 72 h. Similar results were obtained using newly differentiated human pre-adipocytes in primary culture, both under basal conditions and during IL-1 stimulation. CONCLUSION: Our ®ndings indicate that PAI-1 production in human adipose tissue is stimulated by several cytokines (IL-1, TNF-a, TGF-b). Moreover, estrogen and DEXA attenuate the cytokine induced increase in PAI-production. Regarding the PPAR-agonists, no effects of any PPAR-ligand was observed in adipose tissue fragments.
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Splanchnic thermogenesis during increased insulinaglucagon ratios INTRODUCTION: About 20 ± 25% of the resting energy expenditure (REE) in fasting man takes place in the splanchnic tissues. We have previously shown that intake of glucose initially increases splanchnic EE but later reduces the splanchnic oxygen consumption to a level below the fasting control level and have proposed that the reduction in splanchnic oxygen consumption could be due to an inhibition of the hepatic gluconeogenesis. The aim of the present experiments was to measure the in¯uence of different insulina-glucagon ratios on the splanchnic EE. METHODS: Seven healthy normal male subjects were studied twice during a pancreatic island clamp situation, in which the endogenous insulin and glucagon production was abolished by the somatostatin analogue octreotide. In the ®rst experiment (GR) insulin and glucagon was supplemented to keep basal portal vein concentrations. In the other experiment (GD) only insulin was supplemented. These experimental situations gave rise to arterial insulinaglucagon ratios from 1.4 to 10.0. Net substrate balances were studied by Fick's principle. Blood was sampled from an artery and a hepatic vein. Splanchnic blood¯ow was measured by the ICG dye-excretion technique. RESULTS: The arterial concentrations insulin and glucagon, splanchnic oxygen uptake and splanchnic¯uxes of various metabolites are presented in the table. In spite of large differences in glucose output during the clamp in the two experiments, did the splanchnic oxygen uptake decrease nearly to the same extend in both experiments.
CONCLUSION:
The decreased splanchnic oxygen uptake during the pancreatic clamp can not be explained by decreased hepatic gluconeogenesis. Other possible mechanisms will be discussed.
Baseline
Pancreatic clamp
Arterial insulin GR 28 AE 5 7 4 AE 17
Lipid substrates affect glucose uptake and heart muscle GLUT4, UCP2 and UCP3 gene expression in freely moving rats Despite the fact that FFA are the primary energy source for the heart, an increased plasma concentration of FFA may be detrimental for its function during ischemia, leading to an increased incidence of ventricular arrhythmia and death in patient with acute myocardial infarction. An uncoupling effect of FFA on heart metabolism has been described and in the diabetic rat heart a decrease in ATP content has been associated with an increased FFA availability. We aimed therefore to investigate the changes produced by an increased FFA availability on glucose metabolism and on the gene expression of the newly discovered uncoupling proteins UCP2 and 3 at the heart level.
Lean Zucker rats were infused for 24-h with either Intralipid 1 plus heparin or saline. A signi®cant decrease in heart insulin-mediated glucose uptake, as assessed by 2-Deoxy-[ In conclusion an increased availability of FFA may have deleterious effects on heart metabolism due to an impaired insulin sensitivity and glucose uptake, because of a decreased GLUT4 gene expression. Moreover the increase in UCP2 and 3 gene expression may result in an uncoupling of oxidative Dhosphorylation that might deeply affect heart bioenergetics and work capacity.
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Normal lipolytic, but impaired blood¯ow response during b 2 -adrenergic stimulation in obesity SLH Schiffelers 1 , J Akkermans 1 , WHM Saris microdialysis probes were inserted in subcutaneous abdominal adipose tissue. Probes were perfused with 1, 10 and 100 mM dobu-tamine (b 1 -agonist) or salbutamol (b 2 -agonist), each dose for 45 min. Blood¯ow was determined with the ethanol dilution technique. Baseline interstitial glycerol concentrations were similar in both groups. During b 1 -and b 2 -adrenergic stimulation, glycerol concentrations increased similarly in obese and lean men (%change at 100 mM, b 1 : 103 AE 20% vs 79 AE 15%, b: 71AE 18% vs 85 AE 18%, both NS). At baseline, the ethanol outain ratio was similar in both groups. During b 1 -adrenergic stimulation, the ethanol outain ratio decreased similarly in both groups, whereas this decrease was blunted in the obese during b 2 -adrenergic stimulation (ANOVA for treatment x group: P`0.05), indicating a diminished increase in local adipose tissue blood¯ow response (change at 100 mM, b 1 : 70.08 AE 0.02 vs 70.12 AE 0.02, NS; b 2 : 70.08 AE 0.02 vs 70.15 AE 0.02, P`0.05). In summary, b 1 -and b 2 -adrenoceptor-mediated increases in extra-cellular adipose tissue glycerol concentrations were similar in obese and lean men, whereas, the b 2 -adrenoceptormediated local blood¯ow response was impaired in the obese. This suggests that the diminished in vivo b 2 -adrenoceptormediated lipolytic response, as reported earlier by our group 1 is not related to a blunted lipolytic response in the subcutaneous abdominal adipose tissue fat cells, but may possibly be explained by a blunted blood¯ow response in obesity.
1 Schiffelers et al. Br J Clin Pharm 1999; 47:469P-70 .
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Expression of renin-angiotensin system genes in adipocytes of lean and obese normotensive and hypertensive human subjects Center for Molecular Medicine, University Clinic Charite Â, Humboldt-University Berlin, Germany
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The adipose tissue renin-angiotensin system (RAS) has been suggested to play a role in obesity hypertension by contributing to increased angiotensinogen (AGT) plasma levels and increased angiotensin II levels in perivascular adipose tissue. Expression of the AGT gene in human adipose tissue has previously been reported to be positively correlated with body mass index and waist-tohip ratio, but no data are currently available on RAS gene expression in obesity hypertension.
We studied expression of the genes encoding AGT, renin, angiotensinconverting enzyme (ACE), and angiotensin II type 1-receptor (AGTR1) by TaqMan-RT-PCR in isolated human adipocytes obtained by subcutaneous adipose tissue biopsie. Subjects were characterized by anthropometric and 24 h ambulatory blood pressure measurements. Plasma AGT levels and ACE activity, as well as other hormonal and metabolic measurements were also performed. Three groups of subjects were compared: non-obese normotensives (NO-NT, n 12, BMI 22.4 kgam 2 , blood pressure 116a73 mm Hg), obese normotensives (O-NT, n 9, BMI 35.2 kgam 2 , blood pressure 125a79 mm Hg), and obese hypertensives (O-HT, n 9, BMI 33.7 kgam 2 , blood pressure 141a89 mm Hg).
Fasting glucose and insulin levels were lowest in the NO-NT subjects and highest in the O-HT subjects. Plasma leptin was signi®cantly higher in the obese subjects. While plasma AGT was not different between the three groups, plasma ACE was higher in the O-HT subjects compared to p`0.05) . AGT expression in adipocytes was reduced by half in obese subjects compared to lean subjects, but renin expression in O-HT subjects was more than doubled compared to the other groups. ACE expression levels in the obese groups were about twice the level of lean subjects. AGTR1 was slightly higher in obese subjects.
Our study did not con®rm previous ®ndings of increased adipose tissue AGT gene expression in obesity. However, as the expression levels of Renin and ACE are higher in obese subjects, and the absolute mass of adipose tissue is increased in obese individuals, our results do not rule out the hypothesis of increased adipose tissue Ang II formation in obesity. Further studies must demonstrate whether or not increased expression of renin in adipose tissue is linked to obesity associated hypertension or not.
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Low plasma antioxidants and normal plasma B-vitamins and homocysteine in patients with severe obesity and hyperinsulinemia . Plasma vitamin E and carotenoids were measured by HPLC. Folic acid was measured in red blood cells (RBC-FA) and B 12 was measured in plasma. These measures were related to BMI, plasma insulin and homocysteine. RESULTS: Patients with obesity had increased plasma insulin and triglycerides and decreased HDL-cholesterol with normal levels of RBC-FA and plasma B 12 and a non-signi®cant decrease in plasma homocysteine compared to controls (9.4 AE 2.6 vs 11.4 AE 4.8 mmolaL, p 0.07). There was a signi®cant decrease in both plasma carotenoids and vitamin E (0.69 AE 0.32 vs 1.25 AE 0.72 and 24 AE 10 vs 33 AE 14 mgaml), respectively (p`0.01). Both vitamins were signi®-cantly inversely related to BMI and plasma insulin. CONCLUSIONS: Obese patients with BMI above 35 kgam 2 show low plasma antioxidants (carotenoids and vitamin E) and normal B vitamins (B 12 and FA) and plasma homocysteine. This novel observation potentially explains excess cardiovascular morbidity in severe obesity and advocates for an adequate intake of antioxidants in these patients. Workshop 9
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